# A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

> **NCT02215616** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 352 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** Laquinimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02215616
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2018-06-19
- **Final completion:** 2018-06-19
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215616, "A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02215616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*